



## **Xellia Pharmaceuticals Completes Expansion of its Budapest Facilities, Strengthening its Global Anti-infective Product Capabilities**

- *New US\$13m, 3,000m<sup>2</sup> Centralized Laboratory Services Building*
- *Opening ceremony attended by Mr. Peter Szijjártó, Minister of Foreign Affairs and, Mr. Zoltan Kovacs, Major of Kőbánya, a District of Budapest*

**Copenhagen, Denmark, and Budapest, Hungary, 22 August 2017** - Xellia Pharmaceuticals ('Xellia'), a specialty pharmaceutical company focusing on providing important anti-infective treatments against serious and often life-threatening infections, has completed the expansion of its new US\$13m, Centralized Laboratory Services building at its Budapest manufacturing site. The expansion strengthens Xellia's global anti-infective product capabilities with additional product stability and release testing expertise and capabilities.

The new 3,000m<sup>2</sup>, multi-story building accommodates state-of-the-art microbiology and chemical analytical laboratories, a product stability centre and administrative offices. It is conveniently located next to Xellia's current Active Pharmaceutical Ingredient (APIs) manufacturing plant, which employs 250 people.

The new facilities will play a significant role in Xellia's global operational strategy, strengthening its product release and stability testing services for APIs and Finished Dosage Form (FDF) produced across the Company's other sites in the US, China and Denmark. The expansion has resulted in the creation of over 40 new roles within the quality team already and with recruitment still ongoing Xellia is aiming to increase the team at the Centralized Laboratory Services operation to around 80 employees by 2019.

The new facilities were opened today at a formal ceremony where Xellia executives welcomed local dignitaries including Mr. Peter Szijjártó, Minister of Foreign Affairs and, Mr. Zoltan Kovacs, Major of Kőbánya, a district of Budapest.

Carl-Åke Carlsson, Xellia's CEO said; "We would like to thank Mr. Szijjártó, and, Mr. Kovacs, for joining us to celebrate the opening of our superb new facilities. In addition to further enhancing and adding new capabilities, we are continuing to expand our team. We are attracting highly-skilled employees, who have the expertise to help deliver quality assured anti-infective medicines to meet increasing demand from our global customers."

"As anti-microbial drug resistance continues to pose a very real international threat, our work in the production of specialty anti-infectives is more important than ever. Many of the medicines that we manufacture are antibiotics of last resort, used to treat patients when all other treatments have failed. As a world-leading manufacturer we are committed to providing a high quality, secure and safe product supply."

- Ends -

**For more information, please contact:**

**Xellia Pharmaceuticals**

Carl-Åke Carlsson, CEO  
Tel: +45 32 64 55 00

Zsolt Nemeth, General Manager, Budapest  
Tel: +36 1 260 4130

**Instinctif Partners (International media relations)**

Eileen Paul / Ashley Tapp / Melanie Toyne-Sewell  
Tel: +44 (0)1260 296 500  
Email: [xellia@instinctif.com](mailto:xellia@instinctif.com)

**Grayling (Hungary media relations)**

Nóra Lázár  
Tel: +36 1 2667833  
Email: [nora.lazar@grayling.com](mailto:nora.lazar@grayling.com)

Viktória Kokics  
Tel: +36 1 2667833  
Email: [viktoria.kokics@grayling.com](mailto:viktoria.kokics@grayling.com)

**About Xellia**

Xellia Pharmaceuticals is a specialty pharmaceutical company focused on providing important anti-infective treatments against serious and often life-threatening bacterial and fungal infections. With over 100 years of experience Xellia is a leading developer, manufacturer and trusted supplier of fermented and semi-synthetic Active Pharmaceutical Ingredients (APIs) and Injectable Finished Dosage Forms (FDFs) to the pharmaceutical industry. The Company has growing sales in more than 70 countries to over 500 customers across the healthcare industry. Headquartered in Copenhagen, Denmark, Xellia has global facilities including operational and manufacturing capabilities in Denmark, USA, Hungary and China, and currently employs over 1,500 people.

Xellia has a portfolio of specialty anti-infectives, and is a leading supplier of vancomycin and colistimethate sodium (CMS) which together combat life-threatening, multi-drug resistant bacterial infections across Gram-positive and Gram-negative species. Many of these are last resort antibiotics, often used when all other treatments have failed. Xellia is also dedicated to providing new anti-infective treatment options by improving the efficacy and delivery, and reducing toxic side effects of existing products. The Company also has early stage R&D programs focused on the discovery and formulation of new chemical entities effective against resistant microbes, with novel modes of action.

Since July 2013, Xellia has been wholly owned by Novo Holdings A/S, the holding company of the Novo Group.

Further information about Xellia can be found at: [www.xellia.com](http://www.xellia.com).